The U.S. Food and Drug Administration approved its first extended-release injectable regimen for adults with HIV on January 21, 2021. The monthly injection, comprised of cabotegravir and rilpivirine, could replace a daily oral treatment regimen for some adults. Find prescribing information, clinical trials summaries, and teaching slide sets in the NHC's Antiretroviral Medications section. National HIV Curriculum

* The email will not be published on the website.